Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause
Launched by WYETH IS NOW A WHOLLY OWNED SUBSIDIARY OF PFIZER · Sep 13, 2005
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Postmenopausal women of age 40 to 65 seeking treatment for hot flashes with last natural menstrual period (LNMP) completed at least 12 months prior to screening.
- • Minimum of 7 moderate to severe hot flashes per day or 50 per week recorded for 7 consecutive days
- • Body Mass Index less than or equal to 34 kg/m2 using the nomograph for BMI.
- Exclusion Criteria:
- • History, presence, or suspicion of estrogen-dependent neoplasia; Malignancy, or treatment for malignancy, within the previous 2 years.
- • Active or recent arterial thromboembolic disease; History of venous thromboembolism
- • History of cerebrovascular accident, stroke, or transient ischemic attack -
- • Presence of major depressive disorder, bipolar disorder, psychotic disorder, or generalized anxiety disorder requiring therapy
- • Persistent elevated blood pressure
About Wyeth Is Now A Wholly Owned Subsidiary Of Pfizer
Wyeth, now a wholly owned subsidiary of Pfizer, is a global biopharmaceutical company dedicated to advancing healthcare through innovative research and development. With a strong legacy in the pharmaceutical industry, Wyeth focuses on discovering and delivering medicines that address significant medical needs across various therapeutic areas, including vaccines, biologics, and specialty pharmaceuticals. Leveraging Pfizer's extensive resources and expertise, Wyeth continues to drive scientific advancement and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leicester, , United Kingdom
Madrid, , Spain
London, , United Kingdom
Bucuresti, , Romania
Zagreb, , Croatia
Bloemfontein, , South Africa
Paris, , France
Uppsala, , Sweden
Centurion, , South Africa
Oulu, , Finland
Stockholm, , Sweden
Leuven, , Belgium
Kuopio, , Finland
Nijmegen, , Netherlands
Warszawa, , Poland
Zadar, , Croatia
Olomuc, , Czech Republic
Ostrava, , Czech Republic
Prerov, , Czech Republic
Evry, , France
Debrecen, , Hungary
Tatabanya, , Hungary
Del. Cuauhtemoc, , Mexico
Lomas Virrteyes, , Mexico
Den Bosch, , Netherlands
Hengelo, , Netherlands
Katowice, , Poland
Poznan, , Poland
Wroclaw, , Poland
Parow, , South Africa
Linköping, , Sweden
Donetsk, , Ukraine
Kyiv, , Ukraine
Fowey, , United Kingdom
Plymouth, , United Kingdom
Patients applied
Trial Officials
Medical Monitor
Study Director
Wyeth is now a wholly owned subsidiary of Pfizer
Trial Manager
Principal Investigator
For Finland, Sweden, MedInfoNord@wyeth.com
Trial Manager
Principal Investigator
For Ukraine, Romania, WPVIMED@wyeth.com
Trial Manager
Principal Investigator
For Belgium, trials-BEL@wyeth.com
Trial Manager
Principal Investigator
For Czech Republic, WPPGCLI@wyeth.com
Trial Manager
Principal Investigator
For Netherlands, trials-NL@wyeth.com
Trial Manager
Principal Investigator
For Hungary, Croatia, WPBUMED@wyeth.com
Trial Manager
Principal Investigator
For Poland, WVWZMED@wyeth.com
Trial Manager
Principal Investigator
For Mexico, gomezlj@wyeth.com
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials